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Summary The matrix metalloproteinases are a family of enzymes that degrade the extracellular matrix and are considered to be important in
tumour invasion and metastasis. The effect of epidermal growth factor (EGF) on matrix metalloproteinase-1 (MMP1) production in two human
bladder tumour cell lines, RT112 and RT4, has been investigated. In the RT112 cell line, an increase in MMP1 mRNA levels was found after
a 6-h incubation with EGF, and this further increased to 20-fold that of control levels at 24- and 48-h treatment with 50 ng ml-1 of EGF. MMP2
mRNA levels remained constant over this time period, whereas in the RT4 cells no MMP2 transcripts were detectable, but MMP1 transcripts
again increased with 24- and 48-h treatment with 50 ng ml-' of EGF. MMP1 protein concentration in the conditioned medium from both cell
lines increased with 24- and 48-h treatment of the cells and the total MMP1 was higher in the medium than the cells, demonstrating that the
bladder tumour cell lines synthesize and secrete MMP1 protein after continuous stimulation with EGF. MMP1 protein was detected in urine
from patients with bladder tumours, with a significant increase in concentration with increased stage and grade of tumour. MMP1 urine
concentrations may therefore be a useful prognostic indicator for bladder tumour progression.
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The matrix metalloproteinases (MMPs) are a family ofproteolytic
enzymes that contain a zinc atom at their active site. They are
found in both normal and pathological tissue in which matrix
remodelling is involved, including embryonic development,
wound healing, arthritis and angiogenesis, as well as tumour inva-
sion and metastasis (Matrisian, 1990; Liotta et al, 1991). The
enzymes, which are cytoplasmic or membrane type (Sato et al,
1994), are secreted in a latent (pro) form and require activation by
removal ofapproximately 80 amino acids from the propeptide, and
other metalloproteinases and proteases are involved in this activa-
tion (Powell and Matrisian, 1996; Stetler-Stevenson et al, 1996).
Additional regulation of the enzymes is by endogenous tissue
inhibitors ofmetalloproteinases (TIMPS), of which four have now
been identified (Greene et al, 1996). These proteins form a stable
non-covalent complex with the enzymes, inhibiting their activity.
Various members of the MMP family and their inhibitors have
been studied to elucidate their role in cancer, in which deregulation
of their expression and function has been implicated in the inva-
sion of normal tissues by tumours and their subsequent metastatic
spread. Invasive tumour progression is particularly evident in
bladder cancer, in which it is a central feature of the prognostic
staging system. Bladder cancer is the fifth most common cancer in
men, and transitional cell carcinoma (TCC) of the bladder can be
broadly divided into superficial (Ta and T1) or muscle invasive
(T2, T3 and T4) forms. Approximately 50-70% of superficial
tumours recur, but 10-20% will become invasive. At present, there
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is no reliable method to predict which superficial tumours will
show invasive progression or metastasize. In bladder cancer
(Davies et al, 1993) the gelatinases (MMP2 and MMP9) were
found to be higher in invasive than in superficial tumours. MMP2
has also been shown to be elevated in the urine of patients with
TCC ofthe bladder (Margulies et al, 1992). A study by Naruo et al
(1993) reported that mRNA levels of MMP2, TIMP2 and TIMPl
increased in cases with invasion and metastasis ofbladder cancers,
and the ratio of MMP2/TIMP2 increased as invasion and metas-
tasis progressed. In this study, there was also a correlation between
MMP2 and c-fos proto-oncogene expression. A positive correla-
tion between serum TIMPI levels and invasion and metastasis in
patients with bladder cancer has also been reported (Naruo et al,
1994). More recently, it has been reported that the mean serum
MMP2/TIMP2 ratio was higher in patients with recurrence of
urothelial cancer than in those without recurrence and that the
disease-free survival of patients with a high MMP2/TIMP2 ratio
was extremely poor (Gohji et al, 1996a). The elevation of serum
levels of either MMP2 or MMP3, or both, were also shown to be
possible predictors of recurrence in patients with advanced uro-
thelial carcinoma after resection (Gohji et al, 1996b). In contrast
Grignon et al (1996) suggests that there is a strong correlation
between high levels of TIMP2 immunostaining and poor outcome
in patients with invasive bladder cancer.
Growth factors and their receptors are important in tumour
development and progression and several studies have shown that
the presence of epidermal growth factor receptor (EGFR) in
bladder cancer is associated with high tumour stage and grade and
is a strong independent predictor of tumour progression and poor
long-term survival (Lipponen and Eskelinen, 1994; Mellon et al,
1995). Levels of epidermal growth factor (EGF) are known to be
high in urine with a mean value of 80 ng ml-' (Fisher and
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Lakshmanan, 1990), but are lower in patients with bladder
tumours and rise again after surgery (Fuse et al, 1992). Signal
transduction pathways stimulated by EGF induce the activator
protein-i (AP-1) transcriptional regulatory complex (Edwards et
al, 1987), which is a known positive transcriptional regulator of
MMP1 expression (Angel et al, 1987) and stromelysin (MMP3)
(McDonnell et al, 1990) in fibroblasts. We have previously
reported the induction of MMP1 (interstitial collagenase) expres-
sion by EGFR stimulation in the human breast cancer cell line
MDA-MB-23 1 (Nutt and Lunec, 1996).
Here, we report the effect ofEGF on two human bladder tumour
cell lines in relation to MMP1 transcription and translation and
also demonstrate that MMPI can frequently be detected at an
elevated level in the urine of patients with invasive bladder
tumours.
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MATERIALS AND METHODS
Cell culture
Two human bladder tumour cell lines, RT112 and RT4, were
obtained from ECACC. Both cell lines were positive for EGFR,
confirmed by FACS analysis using the method of Brotherick et al
(1994). The cells were grown routinely in medium containing 10%
fetal bovine serum (FBS) and subcultured weekly. The RTI 12
cells were grown in minimum essential medium Eagle with Earle's
salts, and the RT4 cells were grown in RPMI. The cells were nega-
tive for Mycoplasma.
Cells required for treatment were seeded at 2.5x1O6 in large
(145 cm2) Petri dishes in growth medium and incubated for 3 or 4
days, until approximately 50% confluent. The medium was
removed, and the cells were washed twice with phosphate-
buffered saline (PBS) and depleted of serum by addition of
medium containing 0.1% bovine serum albumin (BSA) for 24 h,
apart from some controls that were maintained in 10% FBS.
Serum depletion was used to remove endogenous growth factors.
Fresh medium was then added, both to controls (with either FBS
or 0.1I% BSA) and test plates with 0.1% BSA and EGF (human
recombinant, Sigma-Aldrich, Poole, UK) at 10 or 50 ng ml-' of
medium. The cells were incubated from 30 min to 48 h, after
which time medium was removed from the plates, centrifuged to
remove any cells and frozen at -20°C for measurement of MMP1
concentration. The cells were washed twice with ice-cold PBS,
scraped from the plates and centrifuged. The cell pellets were
stored frozen at -70°C for RNA and protein extraction.
RNA extraction and Northern blot analysis
Total RNA was extracted from the frozen cell pellets using the
phenol-guanidinium isothiocyanate method using a commercial
reagent RNAzol (Biogenesis, Poole, UK), followed by chloroform
extraction and isopropanol precipitation. After washing with
70% ethanol, the RNA pellet was dissolved in water, the concen-
tration determined by absorbance at 260 nm and the samples
stored at -70°C.
Northern blot analysis was performed using the glyoxal method as
previously described (Nutt et al, 1991). Briefly, 20 jig samples of
RNA were treated by glyoxylation before electrophoresis on 1.2%
agarose gel in 10 mm phosphate buffer. The gel was stained with
ethidium bromide to verify equal loading ofsamples before capillary
transfer of the RNA overnight onto Hybond-N nylon membrane
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Figure 1 (A) Northern blot analysis of RNA from RT112 human bladder
tumour cell line treated with EGF as indicated and probed for fos, MMP2 and
18S. (B) Northern blot analysis of RNA from RT112 human bladder tumour
cell line treated with EGF as indicated and probed for MMP1, MMP2 and 18S
(Amersham International, Little Chalfont, UK). After transfer and air
drying, RNA was fixed to the membrane by ultraviolet irradiation
cross-linking for 3.5 min using a mid-range transilluminator
(UltraViolet Products, UK). Radioactive probes were prepared by the
random primer extension method (Feinberg and Vogelstein, 1983).
Probes for c-fos and MMP1 were prepared from cDNA clone inserts,
obtained from A Sharrocks (Newcastle upon Tyne) and P Angel
respectively. Probes for MMP2 and 18S rRNA were prepared by
polymerase chain reaction (PCR) (Clifford et al, 1994) from avail-
able cDNA stocks using primers from published sequences. The
primer pairs used were MMP2: SN 218 5'-CTTGACCAGAATAC-
CATCG-3', ASN 373 5'-ACGAGCAAAGGCATCATCC-3'; 18S:
SN 864 5'-ATGCTCTTAGCTGAGGTGTCC-3', ASN 1154 5'-
AACTACGACGGTATCTGATCG-3'.
PCR products were electrophoresed in a 1.2% low-melting-
point agarose gel and the product detected and yield estimated by
ethidium bromide staining. The product band was cut from the gel,
melted by heating to 65°C and approximately 20-jg aliquots were
used directly in the random primer extension radioactive labelling
reaction, as previously described (Feinberg and Vogelstein, 1983).
After deglyoxylation, the filters were prehybridized at 65°C for
3 h in hybridization solution [0.5 M sodium phosphate buffer, pH
7.0; 1 mM EDTA; 1% BSA; 7% sodium dodecyl sulphate (SDS)]
(Church and Gilbert, 1984) with 1 jg ml-' denatured salmon sperm
DNA, to block non-specific DNA binding sites. Hybridization was
carried out overnight using 106 c.p.m. of probe per ml of hybridiza-
tion solution. The filters were then washed twice in 2 x standard
saline citrate (SSC), 0.2% SDS at 65°C for 5 min and a final wash
for 15 min at 65°C. A high-stringency wash in 0.2 x SSC, 0.2%
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SDS for 15 min was also used for the c-fos and MMP2-probed
filters. To detect the bound radioactivity, the filters were exposed to
a Phosphorlmager screen (Molecular Dynamics, UK). The filters
were stripped in boiling water for 5 min before reprobing, the 18S
rRNA probe being a control for equal sample loading.
Measurement of MMP1 concentration in conditioned
medium, cells and urine
For each sample of cells, 40 ml of conditioned medium was
collected. The conditioned medium from cells was concentrated
eightfold at 4°C using Centricon-10 concentrators (Amicon,
Gloucestershire, UK). The concentrate was used for the measure-
ment of total MMP1 protein using the Biotrak MMP1 ELISA
system (Amersham International, UK) and the results corrected for
the concentration factor. All measurements were performed in
duplicate. The assay is based on a two-site ELISA sandwich format
and MMP1 concentration is determined by optical density readings
at 450 nm and interpolation from a standard curve. Pelleted frozen
cells were lysed by sonication in 1 ml of 50 mm Tris-HCl, pH 7.4.
The sample was centrifuged for 15 min at 10 000 g at 4°C and the
supematant used for the measurement oftotal MMP1 protein.
Urine samples and patient details
Urine samples were collected from patients immediately before
check cystoscopy or cystectomy. Samples were centrifuged and
the supernatant frozen at -20°C. Samples were subsequently
concentrated up to tenfold using the Centricon-10 concentrators
and the concentrate used in the MMPI ELISA assay in duplicate
as above. MMP1 protein concentrations were adjusted for the
concentration factor for each sample. Urine samples were analysed
blind and, retrospectively, the samples were from ten patients with
stage T2-T4 tumours, five stage T1 and 17 stage Ta tumours, and
17 patients who had no detectable tumour at cystoscopy. The stage
of tumour was according to the TNM system and the grade
according to the WHO classification.
RESULTS
Effect of EGF on mRNA in RT112 and RT4 cells
RT112 cells were initially incubated with two concentrations of
EGF for 30 min-6 h. Figure 1A shows the induction of c-fos tran-
scripts as an early response to stimulation of the cells for 0.5 and
1 h with both doses of EGF. The levels ofc-fos mRNA returned to
control values by 2 h. This induction offos mRNA shows that the
bladder tumour cells responded to treatment with EGF. The result
of probing for MMP2 transcripts is also shown in Figure 1, but
these remained constant with both doses of EGF for up to 4 h of
treatment. Reprobing for 18s rRNA demonstrated equal loading
and transfer of RNA in these experiments. Figure 1B shows the
detected transcripts levels for MMPI and MMP2 for up to 6 h of
incubation. Again, MMP2 transcripts remained constant, but by
6 h the levels of MMP1 transcripts were observed to increase,
particularly with the higher dose (50 ng ml-') of EGF. Results of
quantitative analysis for the MMPI transcript signals obtained on
EGF stimulation of the RTI 12 cells showed a twofold increase in
transcripts at 6 h when normalized with 18S levels. Extending the
time course to 24 and 48 h showed a 14-fold increase in transcripts
with 10 ng mlr of EGF and a 20-fold increase with 50 ng ml' of
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Figure 2 (A) Northern blot analysis of RNA from RT112 human bladder
tumour cell line treated with EGF as indicated and probed for MMP1, MMP2
and 18S. CFBS, control in medium containing 10% FBS; CBSA, control in
medium containing 0.10% BSA. (B) Northern blot analysis of RNA from RT4
human bladder tumour cell line treated with EGF as indicated and probed for
MMP1 and 18S. CFBS, control in medium containing 10% FBS; CBSA,
control in medium containing 0.1% BSA
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Figure 3 MMP1 concentration in bladder tumour cells and medium after
EGF stimulation of cells with 10 or 50 ng ml-' EGF and the incubation time
as indicated. The results shown are from one representative experiment,
showing the mean of duplicate measurements where duplicate OD readings
were within 10%
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EGF at both time points (Figure 2A). No induction ofMMP1 tran-
scripts was seen in controls at these time points, and MMP2 tran-
script levels again remained relatively constant over the 48 h time
period in both controls and EGF-treated cells.
RT4 cells were also incubated with two concentrations of EGF
from 1 to 48 h. The results of Northern analysis for MMP1 are
shown in Figure 2B. An eightfold increase in transcripts was seen
at both 24 and 48 h with 50 ng ml EGF treatment, and a twofold
increase with 10 ng ml EGF at 24 h. Again, no increase in MMP1
transcripts was found in controls after 48-h incubation. No MMP2
transcripts were detectable in RNA extracts from the RT4 cells.
MMP1 protein concentration in cells and conditioned
medium
The concentration of total MMP1 protein in conditioned medium
and cell extracts is shown in Figure 3. In RT112 cells, MMP1 was
detected in medium at 24 h and increased at 48 h, whereas levels
in the cells remained constant. In RT4 cells, concentrations of
MMP1 were seen to increase in both the cells and the medium at
24 and 48 h. However, the total amount of MMP1 in medium far
exceeded that in the cells, as 40 ml of medium was collected from
each sample of cells. MMP1 protein was below detectable levels
in medium from cells treated for less than 24 h.
MMP1 protein in urine samples
After concentration of the urine samples, total MMP1 was
detected in a proportion of the samples, as shown in Figure 4A,
where the MMPI concentration is shown in relation to tumour
stage. The normal controls and most patients who were clear of
tumours at cystoscopy were found to have very low or unde-
tectable levels of MMP1. For those patients with tumours,
elevated levels of MMP1 protein were found in the urine of cases
with invasive (T2-T4) tumours compared with samples from
patients with superficial disease only (Ta, TI or cis). Using the
Mann-Whitney T-test, urine from patients with invasive tumours
(T2-T4, n = 10) had statistically significantly higher MMP1
concentrations (median value of 1.23 ng ml-') than the patients
with superficial (Ta-T1, n = 22) tumours, median value of
0.09 ng ml- (P = 0.029) and, in addition, significantly higher
concentrations compared with samples from patients (n = 17) who
were diagnosed as being clear of tumours, median value of
0.0 ng ml-} (P = 0.003). The MMP1 concentration in urine in rela-
tion to tumour grade is shown in Figure 4B. The median values
increase with the tumour grade - 0 ng mll for G1, 0.25 ng ml-l for
G2 and 0.68 ng ml-' for G3 tumours - with a significant difference
between the MMP1 concentration in the urine of patients with G1
and G3 bladder tumours (P < 0.0001).
DISCUSSION
These results demonstrate that the EGFR-positive bladder tumour
cell line RTl 12 responds rapidly to stimulation by EGF, as
evidenced by an increase in the transcript levels of the early
response gene c-fos within 30 min. This is consistent with induc-
tion by EGF of the API transcription factor of which the c-fos
protein product is a part. Later increases in transcripts for MMP1
are also seen as a result ofEGF stimulation in both RT1 12 and RT4
cell lines. The lack ofchange in MMP2 transcript levels after EGF
stimulation of the RT112 cells is further evidence that different
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Figure 4 MMP1 concentration in urine from patients with bladder tumours
(A) with stage of tumour and (B) with grade of tumour
members of the MMP gene family are subject to differential regu-
lation of gene transcription (Benbow and Brinckerhoff, 1997). It is
also interesting that no MMP2 transcript was detectable in the RT4
cells, demonstrating marked differences in the pattern of expres-
sion of this gene family in different cell lines from the bladder.
The concentration of MMP1 found in the conditioned medium
of both bladder tumour cell lines not only demonstrates that, after
EGF stimulation, the cells increase the MMPI mRNA levels but
also that this is translated into increased protein that is secreted by
the epithelial tumour cell lines. It is therefore possible that, in
bladder tumours, it is the epithelial cells rather than the stromal
cells that produce and secrete MMP1 into the urine. It has recently
been reported (Nakopoulou et al, 1997) that MMPI was detected
by immunohistochemistry in the cytoplasm of neoplastic cells in
20% of bladder tumours investigated. The increase in MMP1 in
the medium with time also demonstrates a continual secretion of
the protein into the medium in the continued presence of EGF. In
the RT4 cell line, the increase in mRNA with the two doses of
EGF is not followed exactly by increases in the protein concentra-
tions. This suggests that control of expression may not be just at
the transcriptional level but that translational or post-translational
mechanisms may come into play if protein synthesis is maximal
and the message is still being increased. The higher dose of EGF
used (50 ng ml') is a similar concentration to that in urine (Fisher
and Lakshmanan, 1990), and its effect on the cell lines indicates
that EGF in urine may stimulate bladder tumour cells in vivo to
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increase MMP expression and secretion, and thus contribute to
tumour progression and metastasis. This is similar to the response
of human oral squamous cell carcinoma (SCC) cell lines (Shibata
et al, 1996) in which MMP9 was increased with doses of EGF
greater than 10 ng ml-', which is ten- to 100-fold less than the EGF
concentration in saliva. In the context of bladder cancer, these
observations may also help provide a mechanism to explain the
observation that EGFR expression is more frequently associated
with high tumour stage and grade, and where it is found expressed
in superfical tumours is a strong predictor of invasive progression
when these tumours recur (Mellon et al, 1995). Our initial study
on MMP1 concentrations in the urine of patients with bladder
tumours indicates that higher concentrations of MMPI are
detected in patients with higher stage and higher grade tumours.
The measurement of MMPI in urine may be a useful non-invasive
indication of possible tumour progression, particularly in the
EGFR-positive bladder tumours in which the prognosis is poor.
From a study of MMP1 in colorectal cancer (Murray et al, 1996)
using immunohistochemistry, it was reported that the presence
of MMP1 was associated with poor prognosis and furthermore
showed prognostic significance independent of tumour stage. In
16% (n = 10) of the tumours showing immunoreactivity, more than
90% of tumour cells were positive. MMPI has also been found to
be localized in the carcinoma cells of gastric tumours (Nomura et
al, 1996), whereas in thyroid cancer the MMP1 gene was reported
to be expressed in the fibrous capsules ofpapillary carcinomas and
not in the cancer cells (Kameyama, 1996). MMPI has also been
detected by immunohistochemistry in the tumour cells of some
brain neoplasms (Nakagawa et al, 1994), using in situ hybridization
in head and neck carcinoma (Muller et al, 1993) and also in
pulmonary carcinoma (Urbanski et al, 1992). Thus, MMP1 appears
to be commonly expressed in human tumours, and the present study
shows this to be extended to the detection of elevated MMPI
protein levels in the urine of bladder cancer patients, and this is
associated with invasive high-grade tumours. This is consistent
with the observed induction of MMPI expression in cultured
bladder tumour cells stimulated with EGF and the known associa-
tion of EGFR expression with high tumour stage and grade in
bladder cancer.
These studies further demonstrate the frequent expression of
matrix metalloproteinases in cancer and particularly highlights the
regulation of MMP1, which is now easily detectable in low
concentrations in tumour cells and body fluids with the use of
specific antibodies. The detection ofMMP1 in the urine ofpatients
with invasive bladder tumours requires further investigation and
suggests that early detection of significant levels of the enzyme in
patients with superficial tumours should be tested as a potential
predictor of invasive progression. The causal role of MMP1
expression in tumour invasion and its regulation via EGFR-
dependent signalling pathways should be investigated further.
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